ugn-104

Generic: mitomycin

ugn-104: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.

Development Pipeline (1)

Clinical Trials (1)

A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC)

NCT06774131·Phase 3·URGN
Recruiting

Frequently asked questions

Who is developing ugn-104?

ugn-104 is being developed by UroGen Pharma Ltd..

How many clinical trials involve ugn-104?

BioSniper tracks 1 clinical trial involving ugn-104.

Get deeper analysis on ugn-104

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    ugn-104 — Drug Pipeline, Trials & FDA Status | BioSniper